PTPN13/PTPL1 promoter methylation has been confirmed in a variety of malignancies including non-small cell lung cancer, ovarian cancer, prostate cancer, and breast cancer (Bompard et al., 2002; Castilla et al., 2012; Wang et al., 2022; Wang et al., 2018). Here, PTPN13 is linked to ovarian carcinoma.